RECORD // Company

Nexalin Technology, Inc.

Built 2026-11-22T05:06:24Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Nexalin Technology · Ctgov · exact name match to 'Nexalin Technology, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001829126-26-012319

ItemValuePeriodFormFiledAccessionReport
Revenue$78,3013 months ended 2026-09-3010-Q2026-11-120001829126-26-0123192026-11-22 05:06 UTCReport an error
Net income (loss)$-2,662,0683 months ended 2026-09-3010-Q2026-11-120001829126-26-0123192026-11-22 05:06 UTCReport an error
Interest expense$52,7713 months ended 2026-09-3010-Q2026-11-120001829126-26-0123192026-11-22 05:06 UTCReport an error
Cash and cash equivalents$793,139at 2026-09-3010-Q2026-11-120001829126-26-0123192026-11-22 05:06 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001527352
Ticker
NXL
EIN
275566468
CUSIP
65345B300
Record ID
sx:sec:0001527352

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

22 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
SIC industry3845 Electromedical & Electrotherapeutic Apparatus2026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
State of incorporationDE2026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
Fiscal year end (MMDD)12312026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
Business address1776 YORKTOWN, SUITE 550, HOUSTON, TX, 770562026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
ExchangesNasdaq2026-11-17SEC EDGAR company profile2026-11-22 05:06 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$301,6472025-12-3110-K, XBRL Revenues2026-11-22 05:06 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-8,222,1812025-12-3110-K, XBRL NetIncomeLoss2026-11-22 05:06 UTCReport an error
Total assets (at 2025-12-31)$4,635,3192025-12-3110-K, XBRL Assets2026-11-22 05:06 UTCReport an error
Stockholders' equity (at 2025-12-31)$3,747,9862025-12-3110-K, XBRL StockholdersEquity2026-11-22 05:06 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$654,7832025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 05:06 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-4,957,6582025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 05:06 UTCReport an error
Form D total offering amount (D filed 2011-08-09)$3,525,0002011-08-09D2026-11-22 05:06 UTCReport an error
Form D total amount sold (D filed 2011-08-09)$501,7052011-08-09D2026-11-22 05:06 UTCReport an error
Form D industry groupBiotechnology2011-08-09D2026-11-22 05:06 UTCReport an error
Form D revenue range$1 - $1,000,0002011-08-09D2026-11-22 05:06 UTCReport an error
Form D date of first sale2011-03-162011-08-09D2026-11-22 05:06 UTCReport an error
8-K Item 8.01 (filed 2026-10-01)Other Events On September 30, 2026, Nexalin Technology, Inc. (the “Company”) received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to maintain a closing bid price of at least $1.00 per share (the “Minimum Bid Price Requirement”). As previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, on September 25, 2026, the Company received a written notification (the “Notice”) from the Hearings Panel of the Nasdaq (the “Panel”) granting the Company’s…2026-10-01SEC EDGAR 8-K 0001829126-26-010686 (text as filed, excerpt)2026-11-22 05:06 UTCReport an error
8-K Item 1.01 (filed 2026-10-01)Entry into a Material Definitive Agreement. On September 28, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Distribution Agreement, effective as of September 22, 2026 (the “Agreement”), with the Original Distributors (as defined in the Agreement), acting as founders of, and on behalf of, INOVANEXA MEDICAL TECHNOLOGIES S.A., a Brazilian corporation in formation (the “Distributor”). Under the Agreement, the Company appointed the Distributor as the Company’s exclusive distributor for the importation, distribution, commercialization, promotion and sale of the Company’s Nexalin Sync™ non-invasive neurostimulation device, together with related accessories and disposables (the…2026-10-01SEC EDGAR 8-K 0001829126-26-010685 (text as filed, excerpt)2026-11-22 05:06 UTCReport an error
8-K Item 7.01 (filed 2026-10-01)Regulation FD Disclosure. On October 1, 2026, the Company issued a press release announcing the Company’s entry into the Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set…2026-10-01SEC EDGAR 8-K 0001829126-26-010685 (text as filed, excerpt)2026-11-22 05:06 UTCReport an error
8-K Item 3.01 (filed 2026-09-28)Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on September 1, 2026, Nexalin Technology, Inc. (the “Company”) presented its plan of compliance to the Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) and requested continued listing on Nasdaq and an extension to demonstrate compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) and the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). On…2026-09-28SEC EDGAR 8-K 0001829126-26-010495 (text as filed, excerpt)2026-11-22 05:06 UTCReport an error
8-K Item 5.02 (filed 2026-09-02)Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Carolyn Shelton departed from her role as Senior Vice President of Quality, Regulatory, and Clinical Affairs of Nexalin Technology, Inc. (the “Company”). In connection with her departure, Ms. Shelton and the Company entered into a separation agreement, which provides for one month of continued base salary, a 2026 bonus of $20,000, accelerated vesting of her unvested stock options, up to two years to exercise her vested options, and continued subsidy of her health insurance premiums through September 30, 2026. In exchange, Ms.…2026-09-02SEC EDGAR 8-K 0001829126-26-009659 (text as filed, excerpt)2026-11-22 05:06 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.